Search Results 3501-3510 of 25399 for oral
Participation eligibility · Patients with histological proof (from the primary lesion and/or lymph nodes) of squamous cell carcinoma of the oral cavity, ...
... oral calcineurin inhibitors; high potency or oral steroids). History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing ...
... oral prostanoids, or guanylate cyclase stimulators within 7 days prior to baseline RHC, or planned treatment during the study period; Treatment with inhaled ...
cardiovascular disease, premature birth and low birth weight, rheumatoid arthritis, and eating disorders. Learn more about why paying attention to oral health ...
2016. ENEC Gold Medal for Oral PresentationEuropean Neonatal Ethics Conference. 2013. Award for Special Service University of North Dakota. 2013. Tiongson ...
Subject is recommended for chronic oral anticoagulation therapy (OAC) but has an appropriate rationale to seek a non-pharmacologic alternative. 6. Subject ...
1998. Virginia Winner, Associate Oral Presentation for ResearchAmerican College of Physicians. 1998. National Winner, Associate Abstract Competition for ...
... oral antibiotic therapy or have had at least two episodes of severe CDI resulting in hospitalization may be eligible for the study. Subjects may receive a ...
... oral antibiotics, topical antibiotics, oral corticosteroids, topical corticosteroids, leukotriene receptor antagonist, and interleukin 5 receptor ...
Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y(12) Inhibitor Therapy: A Meta-Analysis. JACC Cardiovasc Interv. 2021 Apr 12; 14 (7):739-750 ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make a gift before July 31 and it can be doubled in impact thanks to a $100,000 Summer Challenge.